ReShape Lifesciences — Investor Presentation (January 2018)
26 slides from ReShape Lifesciences's investor presentation, Jan 31, 2018

Slide 1: Safe Harbor Statement and Risk Factors
Safe Harbor Statement and Risk Factors 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as expect,” “plan,” “anticipate,” “could,”

Slide 2: A medical technology company serving the growing obesity epidemic
Addressing $1.5 billion/year surgical device market¹ Safe, minimally invasive, anatomy preserving solutions with durable outcomes Providing a comprehensive toolbox of solutions for obesity continuum of care 1. Global Bariatric Surgery Devices Market Analysis and Trends, Industry Forecast to 2025, Ac

Slide 3: Obesity: Epidemic, Costly and Underserved
Obesity: Epidemic, Costly and Underserved 4 1The State of Obesity: Better Policies for a Healthier America, 2016. 2McKinsey Global Institute, Overcoming Obesity: An Initial Economic Analysis, pg. 1, November 2014. 3Accuray Research, Bariatric Surgery Devices Market Report. 2017. 4Anterburn DE, Macie

Slide 4: Today's Obesity Continuum (U.S. Populations)
Today's Obesity Continuum (U.S. Populations*) 140 Million Overweight or Obese 65 Million Overweight 60 Million Obese and Severely Obese 15 Million Morbidly Obese Weight Management Surgical Weight Loss Only 1% of patients who qualify receive obesity surgery today Aesthetic Weight Loss *Source: NIH 5

Slide 5: 2015 – 2025 Growth Drivers
2015 – 2025 Growth Drivers More interventions with new procedures Anatomy-friendly Out-patient Improved coverage by payers Therapies proven to address comorbidities Data supporting health economic savings Cost efficiencies vs. drugs 6 Growth of U.S. Obesity and Bariatric Procedures (2011 – 2025E) ht

Slide 6: ReShape: Minimally Invasive Offerings for the Full Continuum of Care
7 ReShape: Minimally Invasive Offerings for the Full Continuum of Care *ReShape Vest is for investigational use only and not approved for use. Vagal nerve stimulation blocks hunger signals Takes up room in the stomach so there is less space for food * Restriction creates feelings of fullness

Slide 7: ReShape Products Meet Patient Requirements
ReShape Products Meet Patient Requirements 8 MINIMALLY INVASIVE LIFESTYLE ENHANCING DURABLE WEIGHT LOSS ReShape products help patients lose weight and live a more comfortable life, while also reducing co-morbidities associated with excess weight ReShape products do not change anatomy and are removab

Slide 8: U.S. Obesity Procedure Mix (2015 – 2025E)
9 2015 2025E ~198,000 Procedures $1.5 Billion ~800,000 Procedures $3.8 Billion *Global Bariatric Surgery Devices Market Analysis and Trends, Industry Forecast to 2025, Accuray Research; Canaccord Genuity Equity Research 2014 U.S. Obesity Procedure Mix (2015 – 2025E)* 9% CAGR Gastric Bypass 22% Ballo

Slide 9: ReShape Intragastric Dual Balloon Technology
ReShape Intragastric Dual Balloon Technology 10 30 – 40 >4,000 Patients Implanted 10.5% 200+ Physicians Implanting 60% Maintained or continued to lose weight (1 year) Acquired in October 2017 FDA approved Endoscopic procedure through the mouth Not anatomy altering Six Month Balloon Implant fills vol

Slide 10: Balloon Patient Results
PATIENT RESULTS AT 48 MONTHS Patients demonstrated improvements in outcomes and comorbidities HbA1c (%) reduction of 0.2 points Systolic blood pressure decreased 6.6 mm Hg Diastolic blood pressure decreased 4.4 mm Hg Improvements in co-morbidities yield significant savings to the health care system

Slide 11: vBloc Bioelectronic Neuroblocking Technology
vBloc® Bioelectronic Neuroblocking Technology 12 35 - 45 Intermittently blocks signals of hunger on the vagus nerve >700 Patients Implanted 4.3” 16 Centers Implanting 25% Implanted subcutaneously Reversible or removable Not anatomy altering FDA Approved EWL at 1 Year** Patient BMI Range* * vBloc The

Slide 12: vBloc Clinical Evidence
50% remittance of metabolic syndrome Systolic blood pressure reduced by 12 mmHg in patients with elevated BP Reduction in LDL “bad” cholesterol of 6.2 mg/dL HbA1c (%) reduction of 1.0 point Highly competitive with leading diabetes drugs 13 vBloc Clinical Evidence CLINICAL STUDY PATIENTS AT 1 YEAR vB

Slide 13: Strategy to Collect Outcomes Data for Reimbursement
14 11. Shikora, Scott, et al. “Vagal Blocking Improves Glycemic Control and Elevated Blood Pressure in Obese Subjects with Type 2 Diabetes Mellitus.” Journal of Obesity, (2013) Article ID 245683. DOI: 10.1155/2013/245683. Study Design Status Kaiser Permanente Diabetes Study vBloc Now Patient Registr

Slide 14: Sales Strategy for vBloc and ReShape
Provide A Compelling, Differentiated Offering Equip Practices For Success Reach & Convert Motivated & Qualified Consumers 15 The ReShape sales team is comprised of 13 direct reps, growing to 16 in 2018 All team members rep all products Three dedicated teams focus on VA, International and U.S./non-VA

Slide 15: ReShape Vest
16 ReShape Vest Wraps around stomach to restrict amount of food eaten; emulates conventional weight loss surgery 85.5% 15” CE Mark Study 1H / 2018 IDE Planned 2H / 2018 Patients Implanted Excess Weight Loss (1 Year)* Acquired May 2017 Not anatomy altering Intended for morbidly obese needing rapid we

Slide 16: Gastric Vest System Pilot Study Outcomes
17 Gastric Vest System Pilot Study Outcomes Efficacious Pilot study patients achieved gold standard of weight loss at 12 months Minimally Invasive Vest is laparoscopic and a removable, anatomy friendly procedure Transformative Technology No other device has TBWL near the standard of bariatric surger

Slide 17: Gastric Vest Clinical Evidence: Reduction in Comorbidities
PILOT STUDY PATIENTS AT 1 YEAR Patients in the Gastric Vest pilot study demonstrated significant improvements in comorbidities HbA1c (%) reduction of 2.1 points Systolic blood pressure decreased 13 mmHg Increase in HDL “good cholesterol” of 29 mg/dL Improvements in co-morbidities yield significant s

Slide 18: Gastric Vest Clinical and Regulatory Path
CE Mark trial Non, randomized trial enrolling 65 patients 12 month primary endpoint (weight loss and safety) 24 month long-term follow-up 19 Gastric Vest Clinical and Regulatory Path US Pivotal Trial (Proposed) Non-randomized trial enrolling up to 250 patients 12 month primary endpoint (weight loss

Slide 19: Intellectual Property
20 Intellectual Property Bioelectronic Medicine Utilizing Vagus Nerve Broad coverage for neuroregulation of vagus nerve/ bioelectronic systems and methods related to neuroblocking, neuromodulation, and neurostimulation technology Coverage of vagus nerve applications including obesity, bulimia, pancr

Slide 20: Strategic Partnership for Neuroregulators and the Vagus Nerve
21 Strategic Partnership for Neuroregulators and the Vagus Nerve Collaboration Agreement (for pre-clinical research) Funded co-development of new modified ReShape Lifesciences‘ products Future opportunities (continued IP + technology platform co-development) Intellectual property licensing ReShape L

Slide 21: ReShape Lifesciences Milestones and Objectives
22 ReShape Lifesciences Milestones and Objectives Reimbursement Grow Pipeline Drive Revenue and Clinical Outcomes Balloon / vBloc commercial coverage Commercial data through clinical use Publish real-world outcomes and co-morbidity data Complete CE Mark trial for Gastric Vest Complete US PMA trial f

Slide 22: Management Team
23 Management Team Dan w. Gladney – Chief Executive officer Health care executive with over 25 years of experience leading a variety of medical device companies Lanx, Heart Leaflet Technologies, ACIST Medical, Compex Technologies; Norwest Equity Partners Scott P. Youngstrom – Chief financial officer

Slide 23: ReShape Lifesciences Inc. contact
ReShape Lifesciences Inc. (NASDAQ:RSLS) 1001 Calle Amanecer San Clemente, CA 92673 Dan Gladney President, Chief Executive Officer & Chairman of the Board 651-634-3089 dwgladney@reshapelifesci.com

Slide 24: pede
pede Lifesciences” ReShape Lifesciences Inc. (NASDAQ:RSLS) 1001 Calle Amanecer San Clemente, CA 92673 Dan Gladney President, Chief Executive Officer & Chairman of the Board 651-634-3089 dwgladney@reshapelifesci.com ©. ReShape

Slide 25: Market Product Positioning
26 Market Product Positioning Alter Anatomy? Diet Restrictions Procedure Type Safety Risks Weight Loss %EWL Procedure Cost By-Pass Yes Severe Laparoscopic Potential for serious complications 65-80% ~$24,000 Sleeve Yes Severe Laparoscopic Potential for serious complications 50-65% ~$19,000 Gastric Ve

Slide 26: By Pi ves Seve -s24000
By Pi ves Seve -s24000 Sleeve Yes re ar (ta) r Sleeve en Laparoscopic | Pol torsacaus | soesy, | 519000 ReShape coe None — | Laparoscople Low 108% oes Vest = EU esc: | Nome | Lasonic | Esteem, | sosox | ison ReShape 2% RARE veloc (RS Nore | Laparccone Low Zhu | -s20000 ReShape ©) so Non tow erenn, |
Source: SEC EDGAR · 8-K filed Jan 31, 2018
More decks from ReShape Lifesciences Inc
EnteroMedics — Investor Presentation (July 2017)27 slides · Jul 26, 2017
EnteroMedics — IPO Roadshow (December 2016)31 slides · Dec 30, 2016
EnteroMedics — Technical Presentation (February 2013)13 slides · Feb 8, 2013
EnteroMedics — Technical Presentation (November 2012)10 slides · Nov 13, 2012
EnteroMedics — Canaccord Genuity Presentation (August 2011)25 slides · Aug 11, 2011
EnteroMedics — IPO Roadshow (November 2010)22 slides · Nov 23, 2010